Effects of bevacizumab on retinal function in isolated vertebrate retina

Lüke, Matthias; Warga, M.; Ziemssen, Focke; Gelişken, Faik; Grisanti, Salvatore; Schneider, Toni; Lüke, Christoph; Partsch, Michael; Bartz‐Schmidt, Karl Ulrich; Szurman, Peter

doi:10.1136/bjo.2006.094995

Cited by 63 publications

(43 citation statements)

References 21 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2006, the Bevacizumab Study Group demonstrated no significant short-term effects of bevacizumab on retinal function of isolated bovine retina, but concluded that long-term effects could not be excluded. 29 In vitro, bevacizumab was shown to be non-toxic or not to alter cell viability of rat neurosensory retinal (R28), 30 retinal ganglion, 31 and medulla-derived PC12 cells 32 or human RPE, 30,33 microvascular endothelial (HMVECad), 30 corneal keratinocyte, 34 corneal fibroblast, 34 and corneal endothelial cells. 34,35 In addition, bevacizumab was demonstrated to reduce VEGF-induced permeability and proliferation of cultured porcine choroidal endothelial cells, 18 inhibit VEGF-stimulated proliferation of monkey choroidal endothelial cells, 33 and inhibit VEGF-induced migration of HUVEC.…”

mentioning

confidence: 99%

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Meyer

Holz

2011

Eye

110

View full text Add to dashboard Cite

Three anti-vascular endothelial growth factor (VEGF) therapies are currently used for the treatment of patients with wet age-related macular degeneration (AMD): pegaptanib, ranibizumab, and bevacizumab. Ranibizumab is an antibody fragment approved for the treatment of wet AMD. Bevacizumab is a fulllength antibody registered for use in oncology but unlicensed for wet AMD. However, it is used off-label worldwide not only for wet AMD but also for various other ocular diseases associated with macular edema and abnormal vessel growth. We consider aspects of ranibizumab and bevacizumab in relation to their molecular characteristics, in vitro and in vivo properties, and preclinical safety data. Before 2009, most studies described the shortterm toxicity of bevacizumab in multiple cell types of the eye. Since 2009, an increasing number of studies have compared the properties of ranibizumab and bevacizumab and investigated their impact on retinal cell functioning. Compared with bevacizumab, ranibizumab neutralizes VEGF better at low concentrations, maintains efficacy for longer, and has a higher retinal penetration and potency. Studies in animals demonstrate ranibizumab to be better localized to the injected eye, whereas bevacizumab appears to have a greater effect in the fellow eye. In humans, a localized and systemic effect has been reported for both molecules. In conclusion, overlapping yet distinct pharmacological properties of ranibizumab and bevacizumab indicate that safety or efficacy data from one cannot be extrapolated to the other.

show abstract

mentioning

confidence: 99%

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Meyer

Holz

2011

Eye

110

View full text Add to dashboard Cite

show abstract

“…Previous studies of bevacizumab have reported a low incidence of systematic and ocular side effects, no retinal toxicity on electrophysiology and histologic evaluations, and no effects on the ganglion cells and RPE apoptosis [17][18][19][20]. However, clinically significant effects have been reported, such as the appearance of marginal cracks, which appears as hypofluorescence around the CNV after IVB for mCNV [22] and an increased number of lacquer cracks [23].…”

Section: Discussionmentioning

confidence: 91%

“…Several investigators have reported the absence of retinal toxicity by electrophysiologic and histologic evaluation, and tissue cultures showed that there were no effects on ganglion cells at an IVB concentration of 2.5 mg/ml and no increase in the rate of retinal pigment epithelial (RPE) cell apoptosis after 48 hours at a concentration of 0.8 mg/ml [17][18][19][20][21]. However, we found marginal crack formation at retinal pigment epithelium (RPE) and choroid level [22], which worsens the visual outcome after IVB for mCNV [23].…”

mentioning

confidence: 99%

Transient Choroidal Thinning after Intravitreal Bevacizumab Injection for Myopic Choroidal Neovascularization

Sayanagi¹,

Jo²,

Ikuno³

2011

J Clinic Experiment Ophthalmol

View full text Add to dashboard Cite

“…[3][4][5] Retina hastalıklarında kullanılan bevacizumabın in vitro çalışmalarda retina pigment epiteli, retina ganglion hücreleri ve kornea endotel hücreleri üzerine toksik etkileri olmadığı bildirilmiştir. [6][7][8] İn vivo olarak da intrakameral uygulanan bevacizumab'ın kornea endoteli üzerine toksik etkisi olmadığı bildirilmiştir. 9 Ranibizumab, neovasküler YBMD'nin tedavisinde etkin bir şekilde kullanılan bir VEGF antagonistidir.…”

Section: Introductionunclassified

İntravitreal Bevacizumab veya Ranibizumab Enjeksiyonu Yapılan Olgularda Kornea Endotelindeki Değişimin Karşılaştırılması

Horozoğlu¹,

Gönen²,

Yaşar³

et al. 2013

tjo

View full text Add to dashboard Cite

ÖzetAmaç: Tek doz intravitreal bevacizumab veya intravitreal ranibizumab enjeksiyonu uygulanan olgularda kornea endotel değişikliklerini karşılaştırmak. Ge reç ve Yön tem: Kliniğimiz retina biriminde diyabetik maküla ödemi, yaşa bağlı maküla dejenerasyonu gibi nedenlerle 1,25 mg/0,05 ml intravitreal bevacizumab ya da 0,5 mg/0,05 ml ranibizumab enjeksiyonu yapılan herhangi bir kornea patolojisi olmayan 27 hastanın 27 gözü retrospektif olarak incelendi. Ondört hastanın 14 gözüne intravitreal ranibizumab, diğer 13 hastanın 13 gözüne ise intravitreal bevacizumab enjeksiyonu yapılmıştı. Enjeksiyon öncesi ve postoperatif 1. hafta ve 1. ayda görme keskinliği, mm2'deki kornea endotel sayısı, göziçi basıncı, pakimetri ölçüm kayıtları incelendi. İstatistiksel analizlerde Mann-Whitney U ve Wilcoxon testleri kullanıldı. So nuç lar: Ortalama yaş 69,3±12,5 (44-85 yıl) idi. Bevacizumab ve ranibizumab gruplarında sırasıyla ortalama kornea endotel sayısı enjeksiyon öncesi 2358,1±487 ve 2348,9±598, enjeksiyon sonrası 1. haftada 2360,8±474,1 ve 2398,3±585,6, enjeksiyon sonrası 1. ayda ise 2315,1±465 ve 2407,4±585,6 idi. Enjeksiyon öncesi ile enjeksiyon sonrası 1. hafta ve 1. ay endotel sayılarındaki değişim her iki grupta da anlamlı bulunmadı (Sırasıyla 1. haftada p=0,953 ve p=0,59; 1. ayda p=0,26 ve p=0,555). Bevacizumab ve ranibizumab gruplarında sırasıyla ortalama merkezi kornea kalınlığı enjeksiyon öncesi 527,3±36,9 ve 544,1±55,5 µm, enjeksiyon sonrası 1. haftada 529,2±49,9 ve 543,5±51,8 µm, enjeksiyon sonrası 1. ayda ise 530,3±55 ve 543,9±46,4 µm idi. Enjeksiyon öncesi ile enjeksiyon sonrası 1. hafta ve 1. ay merkezi kornea kalınlığındaki değişim her iki grupta da anlamlı bulunmadı (Sırasıyla 1. haftada p=0,515 ve p=0,838; 1. ayda p=0,678 ve p=0,444). Tar t›fl ma: İntravitreal olarak tek doz uygulanan 1,25 mg/0,05 ml bevacizumab ya da 0,5 mg/0,05 ml ranibizumab uygulama sonrası 1. hafta ve 1. ayda kornea endotel sayısında anlamlı bir değişikliğe neden olmamaktadır. ( Sum maryPur po se: To compare the corneal endothelial changes after injection of a single-dose intravitreal bevacizumab or intravitreal ranibizumab. Ma te ri al and Met hod:In this retrospective study, we evaluated 27 eyes of 27 patients with either diabetic macular edema or senile macular degeneration, who underwent 1.25 mg/0.05 ml intravitreal bevacizumab or 0.5 mg/0.05 ml ranibizumab injection. None of the patients had corneal pathology. Fourteen eyes of 14 patients received intravitreal ranibizumab, other 13 eyes of 13 patients received intravitreal bevacizumab. We evaluated preoperative and postoperative 1 st week and 1 st month visual acuity, corneal endothelial count at mm 2 , intraocular pressure, and pachymetry results. For statistical analysis, Mann-Whitney U and Wilcoxon tests were used. Re sults: Mean age of the patients was 69.3±12.5 (44-85 year). Average corneal endothelial cell count for bevacizumab and ranibizumab was preoperatively 2358.1±487 and 2348.9±598, postoperative 1. week 2360.8±474.1 and 2398.3±585.6, postoperative 1. month 2315.1±465 a...

show abstract

Effects of bevacizumab on retinal function in isolated vertebrate retina

Abstract: The present study suggests that an intraocular application of 0.25 mg/ml bevacizumab for the treatment of CNV is reasonable. No significant short term effects of bevacizumab on retinal function were detected, but long term effects cannot be excluded.

Cited by 63 publications

References 21 publications

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Transient Choroidal Thinning after Intravitreal Bevacizumab Injection for Myopic Choroidal Neovascularization

İntravitreal Bevacizumab veya Ranibizumab Enjeksiyonu Yapılan Olgularda Kornea Endotelindeki Değişimin Karşılaştırılması

Contact Info

Product

Resources

About